Volume 93, Issue 4 p. 299-301
Commentaries

Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines

D C Swinney

Corresponding Author

D C Swinney

Institute for Rare and Neglected Diseases Drug Discovery, Mountain View, California, USA

Search for more papers by this author
First published: 06 December 2012
Citations: 38

Abstract

Current drug discovery strategies include both molecular and empirical approaches. The molecular approaches are predominantly hypothesis-driven and are referred to as target-based. The empirical approaches are referred to as phenotypic because they rely on phenotypic measures of response. A recent analysis revealed the phenotypic approaches to be the more successful strategy for small-molecule, first-in-class medicines. The rationalization for this success was the unbiased identification of the molecular mechanism of action (MMOA).

Clinical Pharmacology & Therapeutics (2013); 93 4, 299–301. doi:10.1038/clpt.2012.236